<DOC>
	<DOC>NCT00113516</DOC>
	<brief_summary>The purpose of this study is to find out if SU011248 (sunitinib) provides additional benefit when it is given after treatment with two chemotherapy drugs carboplatin and paclitaxel and also if sunitinib is safe for patients with locally advanced and metastatic Non Small Cell Lung Cancer (NSCLC).</brief_summary>
	<brief_title>A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically proven NSCLC Stage IIIB (locally advanced with malignant effusion) or Stage IV disease No prior therapy for NSCLC Evidence of unidimensionally measurable disease Previous treatment with systemic chemotherapy for lung cancer History of or known brain metastases NCI CTCAE Grade 3 hemorrhage within 4 weeks of starting study treatment Evidence of hemoptysis within 4 weeks of starting study treatment Serious acute or chronic illness or recent history of significant cardiac abnormality Previous treatment with antiangiogenesis agents including thalidomide, or inhibitors of EGFR and PDGFR</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Lung Neoplasms</keyword>
</DOC>